Male Patients with the Diagnoses of Synchronous Prostate and Breast Cancer

Chang Yell Lee; Chang Soo Park; Wan Lee; Hee Suk Kwak; Mee Young Sol; Moon Kee Chung

doi:10.4111/kju.2007.48.3.348

Journal List > Korean J Urol > v.48(3) > 1004886

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee, Park, Lee, Kwak, Sol, and Chung: Male Patients with the Diagnoses of Synchronous Prostate and Breast Cancer

Original Article

Korean J Urol 2007;48(3):348-351.

Published online: 18 December 2007

DOI: https://doi.org/10.4111/kju.2007.48.3.348

Male Patients with the Diagnoses of Synchronous Prostate and Breast Cancer

Chang Yell Lee, Chang Soo Park, Wan Lee, Hee Suk Kwak¹, Mee Young Sol², Moon Kee Chung

¹General Surgery

²Pathology, Pusan National University College of Medicine, Busan, Korea

³From the Departments of Urology

Corresponding Author: Jeong Mun-ki Department of Urology, Pusan National University Hospital Ami-dong, Seo-gu, Busan 1st Street 10 602-739 TEL: 051-240-7347 FAX: 051-247-5443 E-mail: mkchung@pusan.ac.kr

Received 30 December 2006 Accepted 21 January 2007

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Prostate cancer and male breast cancer are similar in many ways, including the potential role of steroidal hormones in their pathogenesis and shared genetic abnormalities. However, the combination of these cancers in the same patient is rare. Herein, the case of a male patient, diagnosed with synchronous prostate and breast cancers, is reported. ι

Keywords: Synchronous neoplasms, Prostate cancer, Breast cancer

REFERENCES

1.Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002. 52:23–47.

2.Lopez-Otin C., Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev. 1998. 19:365–96.

3.Ozet A., Yavuz AA., Komurcu S., Ozturk B., Safali M., Arpaci F, et al. Bilateral male breast cancer and prostate cancer: a case report. Jpn J Clin Oncol. 2000. 30:188–90.

4.Leibowitz SB., Garber JE., Fox EA., Loda M., Kaufman DS., Kanto伴PW , et al. Male patients with diagnoses of both breast cancer and prostate cancer. Breast J. 2003. 9:208–12.

5.Karlsson CT., Maimer B., WMund F., Gronberg H. Breast cancer as a second primary in patients with prostate cancerestrogen treatment or association with family history of cancer? J Urol. 2006. 176:538–43.

6.Sigurdsson S., Thorlacius S., Tomasson J., Tryggvadottir L., Benediktsdottir K., Eyfjord JE, et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med. 1997. 75:758–61.

7.Sasco AJ., Lowenfels AB., Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer. 1993. 53:538–49.

8.Diez O., Cortes J., Domenech M., Pericay C., Brunet J., Alonso C, et al. BRCA2 germ-line mutations in Spanish male breast cancer patients. Ann Oncol. 2000. 11:81–4.

9.Valeri A., Fournier G., Morin V., Morin JF., Drelon E., Mangin P, et al. Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. Int J Cancer. 2000. 86:883–7.

10.Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999. 91:1310–6.

Fig. 1.

(A) The tumor cell nests forming a solid mass, with pushing margin infiltrates into normal breast parenchyma (H&E, x100). (B) The tumor cells are large, with prominent nucleoli (H&E, x400).

Fig. 2.

Immunohistochemical staining for the prostate-specific antigen (PSA) (A) and prostate associated protein antigen (PAP) (B) showing negative reactions in a breast ductal carcinoma.

Fig. 3.

(A) The small compact tumor cell nests infiltrating into the normal prostatic parenchyma (H&E, x200). (B) The tumor cells have prominent basophilic nucleoli, which are characteristic of a prostatic adenocarcinoma (H&E, x400).

Fig. 4.

Immunohistochemical staining for the prostate-specific antigen (PSA) (A) and prostate associated protein antigen (PAP) (B) showing

Table 1.

Treatment of patients with male breast cancer and prostate cancer

Patient No./age at diagnosis of cancer		Breast cancer stage	Breast cancer treatment	Prostate cancer diagnosis			Prostate cancer treatment
Patient No./age at diagnosis of cancer		Breast cancer stage	Breast cancer treatment	PSA (ng/ml)	Gleason score	Clinical stage	Prostate cancer treatment
1/47	years⁴	T1N0M0	MRM tamoxifen	4.3	9	T2	Androgen ablation +XRT
2/65	years⁴	T2N1M0	MRM tamoxifen	15.3	8	T2	XRT
3/72	years⁴	T1N0M0	Lumpectomy + XRT+tamoxifen	1.8	6	T2	XRT
4/62	years⁴	T1N0M0	MRM tamoxifen	19.6	7	T2	XRT
5/69	years⁴	T2N0M0	MRM	6.0	6	T2	XRT
6/63	years⁴	T1N0M0	MRM	47.5	8	T3	XRT+tamoxifen
7/67	years⁴	T1N1M0	MRM+XRT	1.9	4	T1a	None
8/66	years⁴	T1N0M0	MRM	11.8	7	T1c	RP
9/68	years⁴	T2N0M0	MRM+XRT + tamoxifen	4.9	6	T1c	None
10/70	years⁴	T?N0M0	MRM	N/A	Poorly differentiated	Metastatic disease to bone	Orchiectomy
11/67	years¹	T?N1M0	MRM+XRT	20.8	6	Metastatic disease to bone	Androgen ablation +XRT
12/61	years∗	T1N0M0	MRM	36.15	7	T2	RP

MRM: modified radical mastectomy, N/A: not applicable, PSA: prostate-specific antigen, RP: radical prostatectomy, XRT: external beam radiation therapy. ∗: author's case

TOOLS

Similar articles